Tyra Biosciences, Inc. (TYRA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $26.04. The rating moved from Neutral to Overbought on August 19, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$26.04
• Last changeMoved from Neutral to Overbought on August 19, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Tyra Biosciences, Inc. (TYRA) is positioned as a higher-risk, catalyst-driven biotech name that stands to benefit from current growth-oriented market flows and sector tailwinds for biologics/oncology R&D. Near-term performance will likely be driven by clinical or corporate milestones, sentiment and financing dynamics; downside remains tied to binary trial outcomes, cash runway and potential dilution. Investors should weigh the prospect of outsized upside on positive news against material volatility and execution risk.

Key factors

• Favorable risk-on market tone and rotation into growth/biotech names supporting near-term multiple expansion
• Biotech/biologics thematic tailwinds (increased interest in oncology/biologics R&D, CDMO demand) that can lift sentiment for clinical-stage names
• Potential upcoming pipeline or clinical milestones that would serve as binary catalysts for meaningful re-rating
• Small-cap / thin-float profile that can amplify moves on positive news or positioning shifts
• Partnership or licensing optionality that could de-risk development and provide non-dilutive capital

Risks

• Binary clinical trial and regulatory risk — adverse data or FDA delays could produce sharp declines
• High cash burn and likely need for additional financing, leading to dilution
• Competitive dynamics in oncology/biologics with larger incumbents and multiple programs pursuing similar mechanisms
• Limited commercial operating history and uncertainty around pricing, reimbursement, and payer dynamics
• Low visibility into short-term fundamentals and limited public financial disclosure increases volatility
• Macro / geopolitical headlines that can reverse risk-on flows and depress speculative biotech performance

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.